PALOMA-2 和 PALLET 研究中跨平台基因表达、计算方法对乳腺癌亚型的影响。
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.
发表日期：2024 Jun 29
作者：
Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A Jacobs, Judith Bliss, Katherine Pogue-Geile, Lucy Kilburn, Zhou Zhu, Eugene F Schuster, Hui Xiao, Lisa Swaim, Shibing Deng, Dongrui R Lu, Eric Gauthier, Jennifer Tursi, Dennis J Slamon, Hope S Rugo, Richard S Finn, Yuan Liu
来源：
npj Breast Cancer
摘要：
内在乳腺癌分子亚型 (IBCMS) 为乳腺癌患者提供重要的预后信息，并帮助确定治疗方法。本研究比较了 PALOMA-2 和 PALLET 试验中各种基因表达平台上的 IBCMS 方法。使用 EdgeSeq 和 nanostring 对 PALOMA-2 肿瘤样本进行分析，并使用 AIMS、PAM50 和仅供研究使用的 (ruo)Prosigna 进行亚型分类。使用 mRNA 测序对 PALLET 肿瘤活检进行分析，并使用 AIMS 和 PAM50 进行亚型分类。在 PALOMA-2 (n = 222) 中，AIMS 和金标准 ruoProsigna 的结果之间观察到 54% 的一致性，AIMS 将 67% 的基础样分配给 HER2 富集的结果。在 PALLET (n = 224) 中，PAM50 和 AIMS 的结果之间观察到 69% 的一致性。不同的 IBCMS 方法可能会导致不同的结果，并可能误导治疗选择；因此，应使用标准化的临床 PAM50 测定和计算方法。试验编号：NCT01740427。© 2024。作者。
Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2 and PALLET trials. PALOMA-2 tumor samples were profiled using EdgeSeq and nanostring and subtyped with AIMS, PAM50, and research-use-only (ruo)Prosigna. PALLET tumor biopsies were profiled using mRNA sequencing and subtyped with AIMS and PAM50. In PALOMA-2 (n = 222), a 54% agreement was observed between results from AIMS and gold-standard ruoProsigna, with AIMS assigning 67% basal-like to HER2-enriched. In PALLET (n = 224), a 69% agreement was observed between results from PAM50 and AIMS. Different IBCMS methods may lead to different results and could misguide treatment selection; hence, a standardized clinical PAM50 assay and computational approach should be used.Trial number: NCT01740427.© 2024. The Author(s).